Affiliation:
1. Beijing Friendship Hospital
2. Peking University Fifth School of Clinical Medicine
3. National Center of Gerontology, Chinese Academy of Medical Sciences
Abstract
Abstract
Objective: To evaluate the effect of inflammatory factors produced by COVID-19 on the prognosis of tumor patients, and the effect of tumors with high expression of such inflammatory factors on the prognosis of COVID-19.
Methods: Combining the GEPIA database with R language software, we analyzed the effects of IL6, TNF, IL2RA and IL10 on the survival of 33 tumors types in the TCGA database. Then we analyzed the effects of inflammatory factors secreted by tumors on the progression and prognosis of COVID-19 using the data published jointly by nine hospitals in Wuhan.
Results: 1, The inflammatory factors IL6, TNF, IL2RA and IL10 produced by COVID-19 have different effects on the prognosis of different types of tumors. IL6 is more sensitive than TNF, IL2RA and IL10 in the assessment of tumor prognosis. 2, Tumors with high expression of IL6 are more likely to progress to severe high-risk case when infected with COVID-19 (severe COVID-19 rates 68.22%, P=0.042), with multiple organ severe damage, high mortality rates(23.36%, P=0.013) and poor prognosis. Tumor patients with high expression of TNF and IL10 also have higher mortality rates after infection with COVID-19 ,which were 23.60% (P= 0.027) and 23.28% (P = 0.007) respectively.
Conclusion: There is a sophisticated interaction between tumor and COVID-19, which IL6, TNF, IL2RA and IL10 produced by COVID-19 will affect the prognosis of tumors, while tumors with high expression of these inflammatory factors will also interfere with the prognosis of COVID-19. IL6 plays a more sensitive role in the evaluation of tumor prognosis of with COVID-19 and the prognosis of COVID-19 with tumor. Active use of IL6 antagonist therapy provides a new treatment idea for tumor patients co-infected with COVID-19.
Implications for Practice: This article supports that IL6 produced by COVID-19 has an effect on the prognosis of various tumors. At the same time, tumors with high expression of IL6 are more likely to progress to severe high-risk case when infected with COVID-19. Active use of IL6 antagonist therapy provides a new treatment idea for tumor patients co-infected with COVID-19.
Publisher
Research Square Platform LLC
Reference23 articles.
1. China National Health Commission, World Health Organization. Epidemic distribution of novel coronavirus [EB/OL]. (2020-09-22) [2020-09-22]. http://2019ncov.chinacdc.cn/2019-nCoV/global.html
2. Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Volume 368. New York, NY): Science; 2020. pp. 473–4. 6490.
3. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet (London, England). 2020;395(10223):497–506.
4. The epidemiological characteristics of an outbreak. of 2019 novel coronavirus diseases (COVID-19) in China][J]. Zhonghua liu xing bing xue za zhi. 2020;41(2):145–151.
5. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J];Yang X;The Lancet Respiratory medicine,2020